Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants").

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend the exercise price, the warrant accelerator terms and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants").

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the "AGM"). Each of the director nominees proposed by management for election were elected to the Board of Directors: Sina Pirooz, Mahmoud Aziz, Kevin Bottomley, Jamie Lewin, and Paul Chow.

Vancouver, British Columbia--(Newsfile Corp. - July 28, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has received approval from the TSX Venture Exchange (the "Exchange") to extend 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months (see July 20, 2022 press release).

Vancouver, British Columbia--(Newsfile Corp. - July 20, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months.

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") Genix is pleased to announce that, pursuant to a Health Canada Drug Establishment License (DEL) inspection, carried out at its warehouse premises on June 22, 2021, the Company has now received a Notice of Compliant Rated Inspection with a compliant (C) rating. This rating means that at the time of the inspection, its activities were fully in compliance with the Food and Drugs Act and its associated regulations and that the Company's DEL has been approved.

Vancouver, British Columbia--(Newsfile Corp. - June 21, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company) is pleased to announce that it has received approval to begin trading its common shares on the OTC Markets Group's OTCQB Venture Market in the United States under the symbol "GENPF". The Company's common shares will begin trading on the OTCQB Marketplace today, June 21st, 2021 and will continue to trade on the TSX Venture Exchange under the symbol "GENX".

Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("Genix" or the "Company"). President, Mr. Mahmoud S. Aziz, provides corporate update.

Vancouver, British Columbia,--(Newsfile Corp. - April 1, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") is pleased to announce that it has entered into an exclusive Canadian licensing and supply agreement (the "Agreement") with Acme Generics LLP ("ACME") for the manufacture, sale, marketing and distribution of Canada's first available generic version of Synthroid® (Levothyroxine sodium), a widely prescribed treatment for hypothyroidism.

Genix Introduces Paul Chow to the Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces the results of its annual general meeting of shareholders ("AGM") held in Vancouver, British Columbia on September 18, 2020.

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" of the "Company") is pleased to announce that it has closed the final tranche of its non-brokered private placement financing announced in its news releases dated June 22 and June 30, 2020. Genix announced the closing for the first tranche in the amount of $640,984 by news release dated July 17th, 2020 news release. The Company has issued 2,572,667 units of the Company (each a "Unit") at a price of $0.15 per Unit. Each Unit consists of one common share of the Company (a "Share") and one-half of one transferrable Share purchase warrant (each whole warrant a "Warrant"). Each Warrant entitles the holder thereof to acquire one additional Share at a price of $0.30 for term of 2 years following closing, being August 8th, 2022 (the "Expiry Date"), subject to acceleration. The proceeds of the final tranche of the financing was $385,750 for a combined total amount raised of $1,026,734.00.

Vancouver, British Columbia--(Newsfile Corp. - July 17, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce it has closed an initial tranche of $640,984 under the non-brokered private placement (the "Private Placement") announced by news release dated June 22, 2020. The Private Placement was originally announced for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. Due to strong demand, Genix filed a price reservation form to increase the size of the Private Placement to total gross proceeds of $1,100,00.

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company and Canagen Pharmaceuticals Inc. ("Canagen") have mutually agreed to extend the closing dates for the payment terms ("Payment Terms") for the sole and exclusive distribution, sales and marketing rights and interest, excluding intellectual property rights, to certain nutraceutical products marketed and distributed under the brand names Renochlor® and Sucanon® as outlined in our news release dated January 14, 2020. The revised Payment Terms will begin with the Initial Payment of $87,500, due and payable within 15 business days from the date Genix receives final TSX Venture Exchange ("TSXV") acceptance to this acquisition. Genix received the TSXV's conditional acceptance to this acquisition on February 4, 2020 however closing is subject to the completion of the Company's previously announced private placement in the amount of $550,000 as described in our news release dated June 22nd, 2020. Genix is proceeding with the private placement and expects to close same as soon as it receives TSXV conditional acceptance to same.

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. The Private Placement will consist of up to 3,750,000 units (excluding any over-allotment) of the Company (each a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferrable Share purchase warrant (each whole warrant a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Share at a price of $0.30 for a period of 2 years following closing of the Private Placement (the "Expiry Date"), subject to acceleration.

A Novel and Proprietary Anti-Viral, Anti-Flu and Common Colds Coronavirus(1) Spray

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2020) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that it has completed the acquisition (the "Acquisition") of 30 World Health Organization approved ophthalmic drugs and product dossiers as stated in its press release dated December 23, 2019. Having received final acceptance to the Acquisition from the TSX Venture Exchange ("TSXV"), the Company issued 15,000,000 common shares to the shareholders of Canagen Pharmaceuticals Inc. to complete the Acquisition. The shares are subject to a resale restriction that expires four months and one day from their date of issuance.

VANCOUVER, Jan. 15, 2020 /CNW/ - Trading resumes in:

TSX Venture Exchange provides conditional acceptance for the acquisition of 30 World Health Organization approved generic ophthalmic drugs

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2019) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company has entered into an Acquisition Agreement dated for reference September 19, 2019 (the "Agreement") and executed October 9, 2019 with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSXV"), the Company has agreed to purchase thirty (30) World Health Organization approved generic prescription ophthalmic drugs (the "Ophthalmic Drugs") and their CTD Dossiers (the "Product Dossiers") together with concomitant global sales and marketing rights (excluding India) to such products in consideration of the issuance of 15,000,000 common shares (the "Vend-In Shares") in the capital of the Company valued at $.05 per Vend-In Share for a total value of $750,000 (the "Transaction"). Under the terms of the Agreement, the Vend-In Shares will be distributed directly to the shareholders of Canagen and no single shareholder shall own more than 10% of the issued and outstanding shares of the Company post Transaction. It is not anticipated that the Transaction will constitute a Change of Business (as that term is defined in the policies of the TSXV).

VANCOUVER, Oct. 29, 2019 /CNW/ - The following issues have been halted by IIROC: